Year: 2025
Type: article
Abstract: Focal Adhesion Kinase (FAK) plays a key role in cancer progression, making it a promising drug target. Hence, we screened 2,000 FDA-approved drugs using two docking tools, PyRx and GOLD. Top hits were analyzed for predicted binding affinities and molecular interactions, and selected compounds were tested in a luminescence-based IC₅₀ assay. Ponatinib emerged as a promising FAK inhibitor, showing favorable binding and measurable activity.
Source: Bioinformation
Authors: Zeel Gandhi, Dale D. Tang, Ajay Nayak, Jitendra D. Belani
Institutions: Thomas Jefferson University, Albany Medical College
Language: English
Subfield: Computational Theory and Mathematics
Field: Computer Science
Domain: Physical Sciences
Open Access status: hybrid
Funder: Thomas Jefferson University
OpenAlex ID: W4414845458
FWCI:
Cites:
Cited by:
Related to: